Back to today’s briefing

Story perspectives

Revolutionary Therapy Boosts Survival in Bladder Cancer Patients

8/13/2025

43 6

Summary

Story summary

Pfizer and Astellas' Padcev, paired with Merck's Keytruda, has demonstrated remarkable improvements in event-free survival for muscle-invasive bladder cancer patients who can't undergo cisplatin-based chemotherapy. This groundbreaking combination therapy, effective both pre- and post-surgery, could redefine treatment standards. The companies are set to share these promising results with regulatory bodies and at an upcoming medical conference.

1 of 1

Story summary

Pfizer and Astellas' Padcev, paired with Merck's Keytruda, has demonstrated remarkable improvements in event-free survival for muscle-invasive bladder cancer patients who can't undergo cisplatin-based chemotherapy. This groundbreaking combination therapy, effective both pre- and post-surgery, could redefine treatment standards. The companies are set to share these promising results with regulatory bodies and at an upcoming medical conference.